Select Publications

Amado RG et al. Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. Gastrointestinal Cancers Symposium 2008;Abstract 278.

Hecht JR et al. Interim results from PACCE: Irinotecan (Iri)/bevacizumab (bev) ± panitumumab (pmab) as first-line treatment (tx) for metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium 2008; Abstract 279.

Wong SL et al. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007;298(18):2149-54. Abstract